Faille A, Blasetti A, Balitrand N, Glückman E, Devergie A, Dresch C
Nouv Rev Fr Hematol (1978). 1984;26(1):13-8.
In vitro bone marrow GM-CFC (granulomonocyte colony forming cell) growth following E rosette (+) cell depletion was studied in 14 aplastic patients to determine whether an autoimmune factor could be involved in the pathophysiological process leading to the decrease in bone marrow colony formation. The increase in GM-CFC growth after E rosette (+) cell depletion was high in 8 cases, suggesting that in these cases an autoimmune mechanism may have been involved. All these patients responded within a month to treatment with antithymocyte globulin (ATG) or corticosteroids. Six patients did not respond to immunotherapy, none showed increased GM-CFC growth. The increase of in vitro GM-CFC growth after E rosette (+) cell depletion in aplastic anemia could therefore be a good indication for the trial of immunotherapy. However this study seems to be useful only in patients with at least a few months evolution after diagnosis.
对14例再生障碍性贫血患者进行了研究,观察E玫瑰花结(+)细胞耗竭后体外骨髓GM-CFC(粒单核细胞集落形成细胞)的生长情况,以确定自身免疫因素是否可能参与导致骨髓集落形成减少的病理生理过程。E玫瑰花结(+)细胞耗竭后GM-CFC生长增加的情况在8例患者中较为明显,提示在这些病例中可能涉及自身免疫机制。所有这些患者在一个月内对抗胸腺细胞球蛋白(ATG)或皮质类固醇治疗有反应。6例患者对免疫治疗无反应,均未显示GM-CFC生长增加。因此,再生障碍性贫血患者E玫瑰花结(+)细胞耗竭后体外GM-CFC生长增加可能是免疫治疗试验的一个良好指标。然而,这项研究似乎仅对诊断后至少有几个月病程的患者有用。